PT  - JOURNAL ARTICLE
AU  - Bright, Roselie A.
AU  - Bright-Ponte, Susan J.
AU  - Palmer, Lee Anne
AU  - Rankin, Summer K.
AU  - Blok, Sergey
TI  - Use of Diagnosis Codes to Find Blood Transfusion Adverse Events in Electronic Health Records
AID  - 10.1101/2020.12.30.20218610
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.12.30.20218610
4099  - http://medrxiv.org/content/early/2021/01/04/2020.12.30.20218610.short
4100  - http://medrxiv.org/content/early/2021/01/04/2020.12.30.20218610.full
AB  - Background Electronic health records (EHRs) and big data tools offer the opportunity for surveillance of adverse events (patient harm associated with medical care). We chose the case of transfusion adverse events (TAEs) and potential TAEs (PTAEs) because 1.) real dates were obscured in the study data, and 2.) there was emerging recognition of new types during the study data period.Objective We aimed to use the structured data in electronic health records (EHRs) to find TAEs and PTAEs among adults.Methods We used 49,331 adult admissions involving critical care at a major teaching hospital, 2001-2012, in the MIMIC-III EHRs database. We formed a T (defined as packed red blood cells, platelets, or plasma) group of 21,443 admissions vs. 25,468 comparison (C) admissions. The ICD-9-CM diagnosis codes were compared for T vs. C, described, and tested with statistical tools.Results TAEs such as transfusion associated circulatory overload (TACO; 12 T cases; rate ratio (RR) 15.61; 95% CI 2.49 to 98) were found. There were also PTAEs similar to TAEs, such as fluid overload disorder (361 T admissions; RR 2.24; 95% CI 1.88 to 2.65), similar to TACO. Some diagnoses could have been sequelae of TAEs, including nontraumatic compartment syndrome of abdomen (52 T cases; RR 6.76; 95% CI 3.40 to 14.9) possibly being a consequence of TACO.Conclusions Surveillance for diagnosis codes that could be TAE sequelae or unrecognized TAE might be useful supplements to existing medical product adverse event programs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research was done with FDA support and under contract HHSF223201510027B between FDA and Booz Allen Hamilton Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:On behalf of the Food and Drug Administration Institutional Review Board (FDA IRB), Karen Ulisney, MSN, CRNP, Human Subject Protection (HSP) Executive Officer, stated the study "does not require FDA IRB review and approval because it is not research involving human subjects as defined in 45 CFR part 46 and it is not an FDA-regulated clinical investigation, as defined in 21 CFR part 56.” Patients/participants were never identified to the authors. The creators of the research dataset at the Massachusetts Institute of Technology (MIT) met the MIT Institutional Review Board requirements. This was not a clinical trial or interventional study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOriginal data (MIMIC-III) are available from https://mimic.physionet.org/about/mimic/ after receiving their permission.95% LCLnormal approximate 95% lower confidence limits 95%UCLnormal approximate 95% upper confidence limitsAEadverse eventsCcomparison group of admissionsEHRselectronic health recordsFDAFood and Drug AdministrationFETFisher’s exact testGIgastrointestinalICD9International Statistical Classification of Diseases and Related Health Problems 9-CMMIMIC-IIIMedical Information Mart for Intensive Care IIINOSNot otherwise specifiedPTAEpotential transfusion adverse eventRDrate differenceRRrate ratioTgroup of transfusion admissionsTACOtransfusion associated circulatory overloadTAEtransfusion adverse eventTRALItransfusion related acute lung injury